

BIOENVISION INC
Form 8-K
October 23, 2007

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

WASHINGTON, D.C. 20549

FORM 8-K

**CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934**

DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED):

October 22, 2007

GENZYME CORPORATION

(Exact name of registrant as specified in its charter)

Massachusetts
(State or other jurisdiction of
incorporation or organization)

0-14680
(Commission file number)

06-1047163
(IRS employer identification
number)

500 Kendall Street, Cambridge, Massachusetts 02142

(Address of Principal Executive Offices) (Zip Code)

Registrant's telephone number, including area code:

(617) 252-7500

Edgar Filing: BIOENVISION INC - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 8.01 Other Events.

On October 22, 2007, Genzyme Corporation announced that the stockholders of Bioenvision, Inc. voted to approve the merger of Wichita Bio Corporation, a wholly-owned subsidiary of Genzyme, with and into Bioenvision. The merger was effective as of 12:01AM EST on October 23, 2007. A copy of the press release is included as Exhibit 99.1 hereto.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

GENZYME CORPORATION

Dated: October 22, 2007

By: /s/ Peter Wirth
Peter Wirth
Executive Vice President and
Chief Legal Officer

Item 9.01 Financial Statements and Exhibits.

(c) Exhibits

99.1 Press Release of Genzyme Corporation dated October 22, 2007.